12,372 trials
Dermatitis, Photoallergic
Primary: Photoallergic Reaction Evaluation Reported as Number of Test Site With Different Erythema Score During Challenge Phase - All Treated Subjects — 325; 24; 343; 6 Test site
Metastatic Pancreatic Adenocarcinoma
Primary: Progression Free Survival (PFS) — 5.32; 6.01 Months — p=<0.0001
Lymphoma
Primary: Number of Participants With Overall Survival (10 Years) by Treatment — 59; 58 Participants
Waldenström's Macroglobulinemia
Primary: Progression Free Survival (PFS) Based on Independent Review Committee (IRC) Assessment - Kaplan Meier Landmark Estimates at Month 54 — 68.0; 25.3; 39.7 percentage of…
Acne
Primary: Mean Percent Change From Baseline in Inflammatory (Papules and Pustules) Lesions — 71.05; 72.84; 51.53 percentage of lesion change
Tobacco Use Disorder
Primary: Tobacco Abstinence — 71; 49; 76; 44 Participants — p=.01
Bronchial Asthma
Primary: Change in FEV1 From Pre Dose to End of Treatment — 0.23; 0.22; 0.09 Litres
Healthcare-associated Pneumonia (HCAP) · Hospital Acquired Pneumonia (HAP) · Ventilator Associated Pneumonia (VAP)
Primary: All-cause Mortality Rate at Day 14 — 12.4; 11.6 percentage of participants — p=0.0020
Malignant Melanoma · Recurrent Melanoma
Primary: Overall Survival (OS) — 7.9; 8.6; 9.1; 7.7 Months
Nicotine Dependence
Primary: Number of Participants With Reported 7-day Point Prevalence Abstinence at Week 12 — 22; 20; 29; 20 Participants
Narcolepsy With Cataplexy
Primary: Change in Weekly Number of Cataplexy Attacks — 0.00; 2.35 attacks
Multiple Myeloma
Primary: Progression Free Survival (PFS) — 9.4; 17.4 months
Pain Associated With Fibromyalgia
Primary: Change From Baseline in Weekly Average Daily Pain Score (ADPS) at Week 13 in Participants Receiving DS-5565, Pregabalin, Placebo — -1.66; -1.90; -1.97; -1.93 units on a…
Nocturia
Primary: Number of Nocturic Episodes at the End of Treatment Compare to Prior to Treatment — -1.4; -1.5; -1.2 nocturic episodes per night
Pain Associated With Fibromyalgia
Primary: Change From Baseline to Week 13 in Average Daily Pain Score (ADPS) Among Participants Receiving DS-5565, Pregabalin, or Placebo — -1.90; -2.64; -2.04; -2.30 units on a…